Mirum Pharmaceuticals (MIRM) Finished Goods (2021 - 2026)

Mirum Pharmaceuticals' Finished Goods history runs 6 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• On a quarterly basis, Finished Goods fell 4.39% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $3.4 million, a 4.39% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, up 7.06% from the prior year.
• Finished Goods slipped to $3.4 million in Q1 2026 per MIRM's latest filing, from $3.5 million in the prior quarter.
• Across five years, Finished Goods topped out at $11.3 million in Q3 2023 and bottomed at $129000.0 in Q1 2023.
• The 5-year median for Finished Goods is $3.4 million (2026), against an average of $3.6 million.
• Across the five-year window, Finished Goods jumped 6200.0% in 2023 and slumped 65.22% in 2024, its largest moves.
• Year by year, Finished Goods stood at $214000.0 in 2022, then surged by 4311.68% to $9.4 million in 2023, then slumped by 65.22% to $3.3 million in 2024, then climbed by 7.06% to $3.5 million in 2025, then dropped by 2.79% to $3.4 million in 2026.
• Per Business Quant, the three latest MIRM Finished Goods figures stand at $3.4 million (Q1 2026), $3.5 million (Q4 2025), and $2.8 million (Q3 2025).